Brought to you by 
Schering AG licenses 3-Dimensional's urokinase inhibitors
12 Sep 2001
Executive Summary
Schering AG licensed exclusive worldwide rights for human therapeutic uses to 3-Dimensional's urokinase inhibitors, paying (uf)$5mm up front through an equity purchase of 625k Series D preferred shares, $5mm in R&D funds, and up to $23mm in milestones for the first product that makes it to market. It will also pay royalties on net sales.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Schering AG licenses 3-Dimensional's urokinase inhibitors
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice